Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai To Deploy Chiome’s MAb Generation Technology

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Chugai Pharmaceutical signed a research agreement with a local Tokyo-based bio venture, Chiome Bioscience to deploy Chiome's Autonomously Diversifying Library system, a monoclonal antibody generation technology for developing monoclonal antibodies against various target proteins owned by Chugai, a Chugai spokesman confirmed Jan. 9

You may also be interested in...



Will 2009 Be The Year Of M&As For Japanese Drug Makers In Antibody Space?

The therapeutic market for monoclonal antibodies has grown exponentially since 2000, and Japanese pharmas, like counterparts in the U.S. and Europe, are looking to antibody drug development as a key-growth driver

Will 2009 Be The Year Of M&As For Japanese Drug Makers In Antibody Space?

The therapeutic market for monoclonal antibodies has grown exponentially since 2000, and Japanese pharmas, like counterparts in the U.S. and Europe, are looking to antibody drug development as a key-growth driver

Japan’s Chugai, Taisho To Seek Approval For Co-Developed Drug

Chugai Pharmaceutical and Taisho Pharmaceutical, both of Japan, plan to submit their eledecalcitol drug for approval in the country. Phase III trials of the vitamin D derivative have been positive, besting a Teijin competitor in comparison trials for treating fractures related to osteoporosis. Chugai, majority-owned by Roche, discovered the drug and is considering foreign trials, according to a spokesman. (Click here for more

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel